|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
February 2005FeaturesCover Story Looking at Biotech’s Crystal BallA look at the issues that will affect our readers this year, as identified by our editorial board. Defining the value of biotech products is the primary concern, though benefit structures, clinician education, funding for innovation, and IT issues loom large. Clinical Practice Build Your Own Infusion ClinicPayers prefer less-costly settings, creating a potentially
lucrative but risky opportunity for private practices. Careful analysis of cost-and-revenue data is the key to success. Regulatory Combination Products and the FDA: Issues and AnswersThese products, like follow-on biologics, generate questions about regulatory pathways. How is the FDA is addressing these issues? Cost Management The 5 Stages of Biotechnology ManagementThe introduction of expensive and complex biotech agents to physicians’ treatment arsenals gives rise to the need for complex economic models that address appropriate demand and the unique qualities of these agents. Leading Edge Better Drug Discovery Through Better Target IdentificationIs HTS a breakthrough or a bust? Second-generation technology holds promise for identifying the best agents for targets earlier in the game. DepartmentsOpeners Out-of-the Box Thinking
Michael D. Dalzell Editorial SEALD With a KissDavid B. Nash, MD, MBA, muses on the future of patient-reported outcomes. Discourse California Vote Spurs Onslaught of State-Level Stem Cell InitiativesCalifornia vote spurs push for stem cell research funding in other states. ECRI Technology Assessment Diagnosing Cancer Earlier with Blood MarkersA look at blood tests on the horizon for cancer. Drugs and Diagnostics CMS Introduces New Payment Rates for Drugs and Their AdministrationCMS payment schedule; FDA actions. Biotech Business Emerging Biotechs’ Greatest Challenge: Acquiring CapitalOne company’s VC strategy. In the Pipeline Today’s Leading Product TechnologiesWhat’s hot? Vaccines, mAbs, proteins. |
|||||